Skip to main content
. 2021 Mar 23;60(8):1015–1027. doi: 10.1007/s40262-021-00990-7

Fig. 3.

Fig. 3

Geometric mean curve of somapacitan full profile on the logarithmic scale in a four kidney impairment groups and the normal function group, and b mild and moderate hepatic impairment groups and the normal hepatic function group